Deutsch
 
Hilfe Datenschutzhinweis Impressum
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT
  Gastric Adenocarcinomas Express the Glycosphingolipid Gb(3)/CD77: Targeting of Gastric Cancer Cells with Shiga Toxin B-Subunit

Geyer, P. E., Maak, M., Nitsche, U., Perl, M., Novotny, A., Slotta-Huspenina, J., et al. (2016). Gastric Adenocarcinomas Express the Glycosphingolipid Gb(3)/CD77: Targeting of Gastric Cancer Cells with Shiga Toxin B-Subunit. Molecular Cancer Therapeutics, 15(5), 1008-1017. doi:10.1158/1535-7163.MCT-15-0633.

Item is

Externe Referenzen

einblenden:

Urheber

einblenden:
ausblenden:
 Urheber:
Geyer, Philipp Emanuel1, Autor           
Maak, Matthias2, Autor
Nitsche, Ulrich2, Autor
Perl, Markus2, Autor
Novotny, Alexander2, Autor
Slotta-Huspenina, Julia2, Autor
Dransart, Estelle2, Autor
Holtorf, Anne2, Autor
Johannes, Ludger2, Autor
Janssen, Klaus-Peter2, Autor
Affiliations:
1Mann, Matthias / Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Max Planck Society, ou_1565159              
2external, ou_persistent22              

Inhalt

einblenden:
ausblenden:
Schlagwörter: HUMAN BREAST-CANCER; HEMOLYTIC-UREMIC SYNDROME; COLON-CANCER; STEM-CELLS; TUMOR; RECEPTOR; BINDING; VEROTOXIN; DELIVERY; PROTEINOncology;
 Zusammenfassung: The B-subunit of the bacterial Shiga toxin (STxB), which is nontoxic and has low immunogenicity, can be used for tumor targeting of breast, colon, and pancreatic cancer. Here, we tested whether human gastric cancers, which are among the most aggressive tumor entities, express the cellular receptor of Shiga toxin, the glycosphingolipid globotriaosylceramide (Gb(3)/CD77). The majority of cases showed an extensive staining for Gb(3) (36/50 cases, 72%), as evidenced on tissue sections of surgically resected specimen. Gb(3) expression was detected independent of type (diffuse/intestinal), and was negatively correlated to increasing tumor-node-metastasis stages (P = 0.0385), as well as with markers for senescence. Gb(3) expression in nondiseased gastric mucosa was restricted to chief and parietal cells at the bottom of the gastric glands, and was not elevated in endoscopic samples of gastritis (n = 10). Gb(3) expression in established cell lines of gastric carcinoma was heterogeneous, with 6 of 10 lines being positive, evidenced by flow cytometry. STxB was taken up rapidly by live Gb(3)-positive gastric cancer cells, following the intracellular retrograde transport route, avoiding lysosomes and rapidly reaching the Golgi apparatus and the endoplasmic reticulum. Treatment of the Gb(3)-expressing gastric carcinoma cell line St3051 with STxB coupled to SN38, the active metabolite of the topoisomerase type I inhibitor irinotecan, resulted in >100-fold increased cytotoxicity, as compared with irinotecan alone. No cytotoxicity was observed on gastric cancer cell lines lacking Gb(3) expression, demonstrating receptor specificity of the STxB-SN38 compound. Thus, STxB is a highly specific transport vehicle for cytotoxic agents in gastric carcinoma. (C) 2016 AACR.

Details

einblenden:
ausblenden:
Sprache(n): eng - English
 Datum: 2016
 Publikationsstatus: Erschienen
 Seiten: 10
 Ort, Verlag, Ausgabe: -
 Inhaltsverzeichnis: -
 Art der Begutachtung: Expertenbegutachtung
 Identifikatoren: ISI: 000375857400022
DOI: 10.1158/1535-7163.MCT-15-0633
 Art des Abschluß: -

Veranstaltung

einblenden:

Entscheidung

einblenden:

Projektinformation

einblenden:

Quelle 1

einblenden:
ausblenden:
Titel: Molecular Cancer Therapeutics
  Andere : Mol. Cancer Ther.
Genre der Quelle: Zeitschrift
 Urheber:
Affiliations:
Ort, Verlag, Ausgabe: Philadelphia, PA : American Association for Cancer Research, Inc.
Seiten: - Band / Heft: 15 (5) Artikelnummer: - Start- / Endseite: 1008 - 1017 Identifikator: ISSN: 1535-7163
CoNE: https://pure.mpg.de/cone/journals/resource/111022849554084